X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2075) 2075
Book Chapter (44) 44
Newspaper Article (9) 9
Magazine Article (7) 7
Newsletter (4) 4
Conference Proceeding (2) 2
Dissertation (1) 1
Streaming Video (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1806) 1806
dabigatran (1527) 1527
science & technology (1526) 1526
life sciences & biomedicine (1503) 1503
anticoagulants - adverse effects (884) 884
anticoagulants (812) 812
male (784) 784
female (725) 725
aged (720) 720
rivaroxaban (695) 695
anticoagulants - therapeutic use (676) 676
atrial fibrillation (659) 659
beta-alanine - analogs & derivatives (648) 648
atrial fibrillation - drug therapy (637) 637
benzimidazoles - adverse effects (631) 631
administration, oral (615) 615
hemorrhage - chemically induced (611) 611
cardiovascular system & cardiology (592) 592
anticoagulants - administration & dosage (534) 534
dabigatran - adverse effects (512) 512
antithrombins - adverse effects (490) 490
stroke - prevention & control (480) 480
warfarin (479) 479
beta-alanine - adverse effects (463) 463
middle aged (455) 455
benzimidazoles - therapeutic use (453) 453
stroke (447) 447
atrial fibrillation - complications (419) 419
aged, 80 and over (406) 406
risk factors (395) 395
treatment outcome (393) 393
apixaban (388) 388
cardiac & cardiovascular systems (379) 379
warfarin - adverse effects (368) 368
benzimidazoles - administration & dosage (358) 358
dabigatran - therapeutic use (314) 314
pharmacology & pharmacy (311) 311
warfarin - therapeutic use (310) 310
beta-alanine - therapeutic use (308) 308
dabigatran etexilate (296) 296
hematology (296) 296
thromboembolism (296) 296
peripheral vascular disease (293) 293
dabigatran - administration & dosage (284) 284
general & internal medicine (276) 276
pyrazoles - adverse effects (276) 276
pyridones - adverse effects (276) 276
antithrombins - therapeutic use (273) 273
abridged index medicus (271) 271
stroke - etiology (271) 271
pyrazoles - therapeutic use (265) 265
pyridones - therapeutic use (265) 265
antithrombins - administration & dosage (257) 257
bleeding (254) 254
medicine, general & internal (251) 251
beta-alanine - administration & dosage (248) 248
pyridines - adverse effects (242) 242
thrombin (230) 230
pyridines - therapeutic use (227) 227
drug therapy (225) 225
prevention (212) 212
pyrazoles - administration & dosage (210) 210
pyridones - administration & dosage (210) 210
cardiac arrhythmia (208) 208
rivaroxaban - adverse effects (208) 208
care and treatment (193) 193
hemorrhage (190) 190
anticoagulation (189) 189
medicine & public health (188) 188
warfarin - administration & dosage (188) 188
thiophenes - therapeutic use (183) 183
morpholines - therapeutic use (182) 182
blood coagulation - drug effects (181) 181
retrospective studies (178) 178
pyridines - administration & dosage (176) 176
morpholines - adverse effects (175) 175
thiophenes - adverse effects (175) 175
patients (174) 174
risk assessment (173) 173
analysis (168) 168
adult (167) 167
thromboembolism - prevention & control (164) 164
rivaroxaban - therapeutic use (160) 160
vitamin k - antagonists & inhibitors (159) 159
dosage and administration (158) 158
venous thromboembolism - prevention & control (153) 153
randomized controlled trials as topic (151) 151
venous thromboembolism (151) 151
cardiology (145) 145
internal medicine (145) 145
rivaroxaban - administration & dosage (141) 141
edoxaban (135) 135
surgery (134) 134
anticoagulants - pharmacokinetics (127) 127
cardiovascular (127) 127
complications and side effects (127) 127
venous thromboembolism - drug therapy (126) 126
hemorrhage - prevention & control (124) 124
dose-response relationship, drug (123) 123
thrombosis (123) 123
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1997) 1997
German (67) 67
French (35) 35
Spanish (28) 28
Russian (24) 24
Japanese (10) 10
Danish (8) 8
Czech (5) 5
Norwegian (5) 5
Hungarian (4) 4
Swedish (4) 4
Dutch (3) 3
Italian (3) 3
Polish (3) 3
Turkish (3) 3
Finnish (2) 2
Arabic (1) 1
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Circulation (New York, N.Y.), ISSN 0009-7322, 07/2016, Volume 134, Issue 3, pp. 248 - 261
.... In addition to familiarity with the dosing and monitoring of vitamin K antagonists, clinicians are accustomed to using vitamin K if there is a need to reverse the anticoagulant effect of vitamin K antagonists... 
anticoagulants | atrial fibrillation | venous thromboembolism | hemorrhage | Cardiac & Cardiovascular Systems | Peripheral Vascular Disease | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Recombinant Proteins - therapeutic use | Plasma | Dabigatran - adverse effects | Pyrazoles - therapeutic use | Humans | Hemorrhage - prevention & control | Recombinant Proteins - adverse effects | Thiazoles - therapeutic use | Factor VIIa - therapeutic use | Arginine - analogs & derivatives | Dabigatran - therapeutic use | Thiazoles - adverse effects | Pyridines - adverse effects | Rivaroxaban - adverse effects | Factor Xa - therapeutic use | Rivaroxaban - therapeutic use | Factor Xa - adverse effects | Pyrazoles - adverse effects | Pyridines - therapeutic use | Antibodies, Monoclonal, Humanized - therapeutic use | Administration, Oral | Antithrombins - therapeutic use | Piperazines - therapeutic use | Dabigatran - antagonists & inhibitors | Piperazines - adverse effects | Factor Xa Inhibitors - therapeutic use | Hemorrhage - drug therapy | Antithrombins - adverse effects | Factor Xa Inhibitors - adverse effects | Blood Coagulation Factors - therapeutic use | Arginine - adverse effects | Pyridones - therapeutic use | Hemorrhage - chemically induced | Hemostatics - therapeutic use | Arginine - therapeutic use | Pyridones - adverse effects | Index Medicus | Abridged Index Medicus
Journal Article
Thrombosis and Haemostasis, ISSN 0340-6245, 01/2009, Volume 101, Issue 1, pp. 77 - 85
.... Risk ratios (RR) for VTE and bleed end-points were estimated using fixed and random effects meta-analysis... 
anticoagulants | thrombosis | prophylaxis | Embolism | Meta-analysis | Anticoagulants | Thrombosis | Prophylaxis | Peripheral Vascular Disease | Life Sciences & Biomedicine | Hematology | Cardiovascular System & Cardiology | Science & Technology | Venous Thromboembolism - mortality | Anticoagulants - administration & dosage | Arthroplasty, Replacement, Knee - adverse effects | Humans | Dabigatran | Enoxaparin - therapeutic use | Enoxaparin - adverse effects | Venous Thromboembolism - prevention & control | Clinical Trials, Phase III as Topic | Enoxaparin - administration & dosage | Pyridines - adverse effects | Benzimidazoles - administration & dosage | Benzimidazoles - adverse effects | Benzimidazoles - therapeutic use | Pyridines - therapeutic use | Pyridines - administration & dosage | Drug Administration Schedule | Risk Assessment | Administration, Oral | Anticoagulants - therapeutic use | Treatment Outcome | Anticoagulants - adverse effects | Arthroplasty, Replacement, Hip - adverse effects | Venous Thromboembolism - etiology | Hemorrhage - chemically induced | Index Medicus | Administration | Phase III as Topic | Benzimidazoles/administration & dosage/adverse effects/therapeutic use | Pyridines/administration & dosage/adverse effects/therapeutic use | Arthroplasty | Replacement | Oral | Clinical Trials | Kirurgi | Knee/adverse effects | Hemorrhage/chemically induced | Venous Thromboembolism/etiology/mortality/prevention & control | Hip/adverse effects | Anticoagulants/administration & dosage/adverse effects/therapeutic use | Surgery | Enoxaparin/administration & dosage/adverse effects/therapeutic use
Journal Article
Thrombosis and Haemostasis, ISSN 0340-6245, 03/2012, Volume 107, Issue 3, pp. 584 - 589
Journal Article
International Journal of Cardiology, ISSN 0167-5273, 2014, Volume 179, pp. 279 - 287
Journal Article
Journal Article
Thrombosis and Haemostasis, ISSN 0340-6245, 04/2014, Volume 111, Issue 4, pp. 575 - 582
Journal Article
Circulation (New York, N.Y.), ISSN 1524-4539, 02/2014, Volume 129, Issue 7, pp. 764 - 772
Dabigatran and warfarin have been compared for the treatment of acute venous thromboembolism (VTE) in a previous trial. We undertook this study to extend those... 
Antagonists & inhibitors | Recurrence | Thrombin | Warfarin | Hemorrhage | Venous thromboembolism | Cardiac & Cardiovascular Systems | Peripheral Vascular Disease | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Anticoagulants - administration & dosage | Follow-Up Studies | Humans | Middle Aged | Heparin - administration & dosage | Heparin, Low-Molecular-Weight - adverse effects | Warfarin - adverse effects | Male | Antithrombins - administration & dosage | Dabigatran | Heparin - adverse effects | Warfarin - administration & dosage | Venous Thromboembolism - drug therapy | Young Adult | Benzimidazoles - administration & dosage | Adult | Female | Benzimidazoles - adverse effects | Venous Thromboembolism - epidemiology | beta-Alanine - analogs & derivatives | Acute Disease | beta-Alanine - adverse effects | Double-Blind Method | Hemorrhage - epidemiology | Risk Factors | beta-Alanine - administration & dosage | Anticoagulants - adverse effects | Antithrombins - adverse effects | Adolescent | Aged | Hemorrhage - chemically induced | Heparin, Low-Molecular-Weight - administration & dosage | Usage | Care and treatment | Dabigatran etexilate | Thromboembolism | Index Medicus | Abridged Index Medicus | Anticoagulants | Benzimidazoles | Heparin, Low-Molecular-Weight | Life Sciences | Venous Thromboembolism | Antithrombins | Heparin | beta-Alanine
Journal Article
American Journal of Emergency Medicine, ISSN 0735-6757, 2016, Volume 34, Issue 11, pp. 46 - 51
... to their favorable safety, efficacy, and ease of use when compared with warfarin [2,3]. As expected with antithrombotic drugs, bleeding is the most common adverse event... 
Emergency | Life Sciences & Biomedicine | Emergency Medicine | Science & Technology | Piperazines - administration & dosage | Recombinant Proteins - therapeutic use | Factor Xa - administration & dosage | Dabigatran - adverse effects | Humans | Clinical Protocols | Hemorrhage - prevention & control | Thiazoles - antagonists & inhibitors | Recombinant Proteins - adverse effects | Arginine - analogs & derivatives | Thiazoles - adverse effects | Arginine - administration & dosage | Patient Selection | Pyridines - antagonists & inhibitors | Pyridines - adverse effects | Antibodies, Monoclonal, Humanized - administration & dosage | Rivaroxaban - adverse effects | Emergency Treatment | Factor Xa - therapeutic use | Factor Xa - adverse effects | Pyrazoles - adverse effects | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Surgical Procedures, Operative | Piperazines - therapeutic use | Pyridones - antagonists & inhibitors | Dabigatran - antagonists & inhibitors | Anticoagulants - adverse effects | Piperazines - adverse effects | Recombinant Proteins - administration & dosage | Hospitals | Factor Xa Inhibitors - adverse effects | Arginine - adverse effects | Rivaroxaban - antagonists & inhibitors | Hemorrhage - chemically induced | Arginine - therapeutic use | Pyrazoles - antagonists & inhibitors | Pyridones - adverse effects | Practice Guidelines as Topic | Periodical publishing | Anticoagulants (Medicine) | Prothrombin | Thrombin | Comorbidity | Anticoagulants | FDA approval | Laboratories | Hemorrhage | Index Medicus
Journal Article